Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use.
The anti-proliferative activities of all twenty-five targeted kinase inhibitor drugs that are in clinical use were measured in two large assay panels: (1) a panel of proliferation assays of forty-four human cancer cell lines from diverse tumour tissue origins; and (2) a panel of more than 300 kinase...
Main Authors: | Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jos de Man, Yoshinori Tanizawa, Yusuke Kawase, Kohichiro Yoshino, Rogier C Buijsman, Guido J R Zaman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3961306?pdf=render |
Similar Items
-
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
by: Joost C M Uitdehaag, et al.
Published: (2015-01-01) -
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
by: Yvonne Grobben, et al.
Published: (2021-01-01) -
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158
by: Yvonne Grobben, et al.
Published: (2020-01-01) -
A theoretical entropy score as a single value to express inhibitor selectivity
by: Zaman Guido JR, et al.
Published: (2011-04-01) -
Cluster headache: new targets and options for treatment [version 1; referees: 2 approved]
by: Patty Doesborg, et al.
Published: (2018-03-01)